Key result
Partial IGF-1 deficiency in mice reduced basal heart contractility and angiotensin II sensitivity, and resulted in an abnormal response to ischemia-reperfusion (dP/dt 1140 vs 644 mmHg/s in controls).
Why the study?
Does recombinant human IGF-1 therapy improve heart contractility, angiotensin II sensitivity, and cardiac structure in a mouse model of partial IGF-1 deficiency?
Does recombinant human IGF-1 therapy improve heart contractility, angiotensin II sensitivity, and cardiac structure in a mouse model of partial IGF-1 deficiency?
Partial IGF-1 deficiency in mice impairs cardiac contractility and angiotensin II sensitivity while inducing fibrosis, all of which are reversible with short-term IGF-1 replacement.
Answers are grounded in this paper and cite their sources.
Caution against clinical extrapolation from murine IGF-1 data; leaves open human relevance for heart failure therapies.
Circulating levels of IGF-1 may decrease under several circumstances like ageing, metabolic syndrome, and advanced cirrhosis. This reduction is associated with insulin resistance, dyslipidemia, progression to type 2 diabetes, and increased risk for cardiovascular diseases. However, underlying mechanisms between IGF-1 deficiency and cardiovascular disease remain elusive. The specific aim of the present work was to study whether the partial IGF-1 deficiency influences heart and/or coronary circulation, comparing vasoactive factors before and after of ischemia-reperfusion (I/R). In addition, histology of the heart was performed together with cardiac gene expression for proteins involved in structure and function (extracellular matrix, contractile proteins, active peptides); carried out using microarrays, followed by RT-qPCR confirmation of the three experimental groups. IGF-1 partial deficiency is associated to a reduction in contractility and angiotensin II sensitivity, interstitial fibrosis as well as altered expression pattern of genes involved in extracellular matrix proteins, calcium dynamics, and cardiac structure and function. Although this work is descriptive, it provides a clear insight of the impact that partial IGF-1 deficiency on the heart and establishes this experimental model as suitable for studying cardiac disease mechanisms and exploring therapeutic options for patients under IGF-1 deficiency conditions.
No takes yet. Share an insight, caveat, or question.
González-Guerra et al. (2017) studied Partial IGF-1 deficiency (n=60). Partial IGF-1 deficiency vs. Wild-type mice was evaluated on Left ventricular contractility (dP/dt) after ischemia-reperfusion (p=<0.05). Partial IGF-1 deficiency in mice reduced basal heart contractility and angiotensin II sensitivity, and resulted in an abnormal response to ischemia-reperfusion (dP/dt 1140 vs 644 mmHg/s in controls).
Synapse has enriched 10 related papers. Consider them for comparative context: